Scientific Platforms
We’re here to make an impact. At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving science in new directions and breaking new ground.
PIPELINE
PRECLINICAL
IND-ENABLING
PHASE 1
PHASE 2
PHASE 3
Vaccines
Gene Therapies
ASSET/ PROGRAM
OCU400
AAV-hNR2E3
Received orphan drug designation
INDICATION
Treatment of NR2e3, RHO and CEP290 Mutations
PHASE
Phase 1/2
ASSET/ PROGRAM
OCU410
AAV-hRORA
INDICATION
Dry Age-Related Macular Degeneration (Dry AMD)
PHASE
IND-Enabling
Biologicals
ASSET/ PROGRAM
OCU200
Transferrin-Tumstatin
INDICATION
Diabetic Macular Edema, Diabetic Retinopathy and Wet Age-Related Macular Degeneration (Wet AMD)
PHASE
IND-Enabling
STAY CONNECTED
Contact us for more information
Copyright @ 2021.